Sumit Sohal

Dr. Sumit Sohal

Newark Beth Israel Medical Center, Newark, California, USA
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Clinical Medicine Insights: Cardiology
Verified
Journal Article
Open access
PDF file
Dinesh K. KalraDinesh K. Kalra
Dinesh K. Kalra
ARAnvi Raina
Anvi Raina
SSSumit Sohal
Sumit Sohal
Neurogenic orthostatic hypotension (nOH) is a subtype of orthostatic hypotension in which patients have impaired regulation of standing blood pressure due to autonomic dysfunction. Several primary and secondary causes of this disease exist. Patients may present with an array of symptoms making diagnosis difficult. This review article addresses the epidemiology, pathophysiology, causes, clinical features, and management of nOH. We highlight various pharmacological and non-pharmacological approaches to treatment, and review the recent guidelines and our approach to nOH.

2 August 2022 in Current Cardiology Reports
Verified
Journal Article
Closed access
PDF file
SSSumit Sohal
Sumit Sohal
SMSheetal Vasundara Mathai
Sheetal Vasundara Mathai
KLKevin Lipat
Kevin Lipat
AKArpanjeet Kaur
Arpanjeet Kaur
GVGautam Visveswaran
Gautam Visveswaran
EVEsad Vucic
Esad Vucic

6 February 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
AKArpanjeet Kaur
Arpanjeet Kaur
ADArshdeep S. Dhaliwal
Arshdeep S. Dhaliwal
SSSumit Sohal
Sumit Sohal
YGYeongjin Gwon
Yeongjin Gwon
SGSoumya Gupta
Soumya Gupta
JTJacqueline Tamis‐Holland
Jacqueline Tamis‐Holland
Background: Cerebral embolic protection devices (CEPD) capture embolic material in an attempt to reduce ischemic brain injury during transcatheter aortic valve replacement. Prior reports have indicated mixed results regarding the benefits of these devices. With new data emerging, we performed an updated meta‐analysis examining the effect of CEPD during transcatheter aortic valve replacement on various clinical, neurological, and safety parameters. Methods and Results: A comprehensive review of electronic databases was performed comparing CEPD and no‐CEPD in transcatheter aortic valve replacement. Primary clinical outcome was all‐cause stroke. Secondary clinical outcomes were disabling stroke and all‐cause mortality. Neurological outcomes included worsening of the National Institutes of Health Stroke Scale score, Montreal Cognitive Assessment score from baseline at discharge, presence of new ischemic lesions, and total lesion volume on neuroimaging. Safety outcomes included major or minor vascular complications and stage 2 or 3 acute kidney injury. Seven randomized controlled trials with 4016 patients met the inclusion criteria. There was no statistically significant difference in the primary clinical outcome of all‐cause stroke; secondary clinical outcomes of disabling stroke, all‐cause mortality, neurological outcomes of National Institutes of Health Stroke Scale score worsening, Montreal Cognitive Assessment worsening, presence of new ischemic lesions, or total lesion volume on diffusion‐weighted magnetic resonance imaging between CEPD versus control groups. There was no statistically significant difference in major or minor vascular complications or stage 2 or 3 acute kidney injury between the groups. Conclusions: The use of CEPD in transcatheter aortic valve replacement was not associated with a statistically significant reduction in the risk of clinical, neurological, and safety outcomes.

4 February 2022 in Future Cardiology
Verified
Journal Article
Closed access
NTNidhish Tiwari
Nidhish Tiwari
SNSanjana Nagraj
Sanjana Nagraj
ATAndreas Tzoumas
Andreas Tzoumas
AAAngelos Arfaras-Melainis
Angelos Arfaras-Melainis
AKAdarsh Katamreddy
Adarsh Katamreddy
LPLeonidas Palaiodimos
Leonidas Palaiodimos
Aim: The role of coronary computed tomography angiography (CCTA) in evaluating the etiology of heart failure with reduced ejection fraction (HFrEF) is unclear. This is a meta-analysis assessing the... Plain language summary The role of ‘CAT scan,’ a computerized series of x-rays, in determining the cause of heart failure with low pumping capacity of the heart is unclear. We conducted a study to ... Graphical abstract Tweetable abstract CCTA has excellent diagnostic accuracy for detecting significant coronary artery disease in patients with newly diagnosed heart failure with reduced ejection fraction. It is a no...

19 September 2022 in Journal of Interventional Cardiology
Verified
Journal Article
Open access
SSSumit Sohal
Sumit Sohal
HMHarsh Mehta
Harsh Mehta
KKKrishna Kurpad
Krishna Kurpad
SMSheetal Vasundara Mathai
Sheetal Vasundara Mathai
RTRajiv Tayal
Rajiv Tayal
MCMarc Cohen
Marc Cohen
Declining Trend of Transapical Access for Transcatheter Aortic Valve Replacement in Patients with Aortic Stenosis: Introduction. The last decade has witnessed major evolution and shifts in the use of transcatheter aortic valve replacement (TAVR) for severe aortic stenosis (AS). Included among the shifts has been the advent of alternative access sites for TAVR. Consequently, transapical access (TA) has become significantly less common. This study analyzes in detail the trend of TA access for TAVR over the course of 7 years. Methods. The national inpatient sample database was reviewed from 2011–2017 and patients with AS were identified by using validated ICD 9-CM and ICD 10-CM codes. Patients who underwent TAVR through TA access were classified as TA-TAVR, and any procedure other than TA access was classified as non-TA-TAVR. We compared the yearly trends of TA-TAVR to those of non-TA-TAVR as the primary outcome. Results. A total of 3,693,231 patients were identified with a diagnosis of AS. 129,821 patients underwent TAVR, of which 10,158 (7.8%) underwent TA-TAVR and 119,663 (92.2%) underwent non-TA-TAVR. After peaking in 2013 at 27.7%, the volume of TA-TAVR declined to 1.92% in 2017 ( ). Non-TA-TAVR started in 2013 at 72.2% and consistently increased to 98.1% in 2017. In-patient mortality decreased from a peak of 5.53% in 2014 to 3.18 in 2017 ( ) in the TA-TAVR group and from a peak of 4.51% in 2013 to 1.24% in 2017 ( ) in the non-TA-TAVR group. Conclusion. This study highlights a steady decline in TA access for TAVR, higher inpatient mortality, increased length of stay, and higher costs compared to non-TA-TAVR.

1 January 2019 in Journal of Clinical Medicine Research
Verified
Journal Article
Open access
PDF file
MAMohammed Abdalla
Mohammed Abdalla
SSSumit Sohal
Sumit Sohal
BABaha’a Al-Azzam
Baha’a Al-Azzam
WMWiam Mohamed
Wiam Mohamed
Effect of Troponin I Elevation on Duration of Mechanical Ventilation and Length of Intensive Care Unit Stay in Patients With Sepsis